Grants and Contributions:
Title:
ARP - Feasibility - Development of new applications for the Opkemo nanomedicine platform.
Agreement Number:
1012956
Agreement Value:
$75,000.00
Agreement Date:
Dec 4, 2023 - Oct 31, 2024
Description:
Development of new silica-based nanovector formulations for sustained release of active pharmaceutical ingredients, similar to metronomic chemotherapy.
Organization:
National Research Council Canada
Expected Results:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Location:
Quebec, Quebec, CA G1P 4S6
Reference Number:
172-2023-2024-Q3-1012956
Agreement Type:
Contribution
Report Type:
Grants and Contributions
Recipient Business Number:
743257313
Recipient Type:
For-profit organization
Recipient's Operating Name:
Pharma in silica
Recipient's Legal Name:
Laboratoires Pharma in silica inc.
Federal Riding Name:
Québec
Federal Riding Number:
24059
Program:
Industrial Research Assistance Program – Contributions to Firms
Program Purpose:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Coverage:
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation.
NAICS Code:
325410